Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by Huazhong University of Science and Technology.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00360763
First received: August 4, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
  Purpose

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.


Condition Intervention Phase
Hypertension
Drug: candesartan cilexetil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Huazhong University of Science and Technology:

Estimated Enrollment: 600
Estimated Study Completion Date: December 2006
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hypertension (2 grade)

Exclusion Criteria:

  • Secondary hypertension
  • Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00360763

Locations
China, Hubei
Department of Cardiology, Wuhan Union Hospital Recruiting
Wuhan, Hubei, China, 430022
Contact: Yu-Hua Liao, Doctor    00862785726376    yumiaowei@vip.sina.com   
Sponsors and Collaborators
Huazhong University of Science and Technology
Investigators
Study Director: Yu-Hua Liao Union Hospital, Tongji Medical College
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00360763     History of Changes
Other Study ID Numbers: UH-01
Study First Received: August 4, 2006
Last Updated: August 4, 2006
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Candesartan cilexetil
Candesartan
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 19, 2014